CS-2826
| 中文名称 | CS-2826 |
|---|---|
| 中文同义词 | (S)-N-(1-(1H-苯并[D]咪唑-2-基)-4-(2-氯乙酰亚胺基)丁基)-[1,1'-联苯基]-4-甲酰胺;化合物BB-CL-AMIDINE;(S)-N-(1-(1H-苯并[D]咪唑-2-基)-4-(2-氯乙酰亚胺基)丁基)-[1,1'-联苯基]-4-甲酰胺 |
| 英文名称 | BB-Cl-Amidine |
| 英文同义词 | BB-Cl-Amidine;CS-2826;N-{(1S)-1-(1H-Benzimidazol-2-yl)-4-[(2-chloroethanimidoyl)amino]butyl}-4-biphenylcarboxamide;[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-;Peptidylarginine Deiminase,Inhibitor,BBClAmidine,BB Cl Amidine,Protein Arginine Deiminase,inhibit;(S)-N-(1-(1H-Benzo[d]imidazol-2-yl)-4-(2-chloroacetimidamido)butyl)-[1,1'-biphenyl]-4-carboxamide;N-[(1S)-1-(1H-1,3-benzodiazol-2-yl)-4-(2-chloroethanimidamido)butyl]-[1,1'-biphenyl]-4-carboxamide |
| CAS号 | 1802637-39-3 |
| 分子式 | C26H26ClN5O |
| 分子量 | 459.971 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 1802637-39-3.mol |
| 结构式 |  |
CS-2826 性质
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
|---|---|
| 溶解度 | DMSO:76.33(Max Conc. mg/mL);165.94(Max Conc. mM) DMF:20.0(Max Conc. mg/mL);43.48(Max Conc. mM) Water:70.0(Max Conc. mg/mL);152.18(Max Conc. mM) Ethanol:54.5(Max Conc. mg/mL);118.48(Max Conc. mM) Ethanol:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.09(Max Conc. mM) |
| 形态 | 结晶固体 |
BB-Cl-Amidine 是肽基精氨酸脱胺酶 (PAD) 的抑制剂。
PAD.
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely.
| Animal Model: | MRL/lpr mice. |
| Dosage: | 1 mg/kg. |
| Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. |
| Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |